151 related articles for article (PubMed ID: 28830787)
1. Epigenetic dysregulation in adrenocortical carcinoma, a systematic review of the literature.
Jonker PKC; Meyer VM; Kruijff S
Mol Cell Endocrinol; 2018 Jul; 469():77-84. PubMed ID: 28830787
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive DNA methylation analysis of benign and malignant adrenocortical tumors.
Fonseca AL; Kugelberg J; Starker LF; Scholl U; Choi M; Hellman P; Åkerström G; Westin G; Lifton RP; Björklund P; Carling T
Genes Chromosomes Cancer; 2012 Oct; 51(10):949-60. PubMed ID: 22733721
[TBL] [Abstract][Full Text] [Related]
3. Integrated genome-wide analysis of genomic changes and gene regulation in human adrenocortical tissue samples.
Gara SK; Wang Y; Patel D; Liu-Chittenden Y; Jain M; Boufraqech M; Zhang L; Meltzer PS; Kebebew E
Nucleic Acids Res; 2015 Oct; 43(19):9327-39. PubMed ID: 26446994
[TBL] [Abstract][Full Text] [Related]
4. Pathway Implications of Aberrant Global Methylation in Adrenocortical Cancer.
Legendre CR; Demeure MJ; Whitsett TG; Gooden GC; Bussey KJ; Jung S; Waibhav T; Kim S; Salhia B
PLoS One; 2016; 11(3):e0150629. PubMed ID: 26963385
[TBL] [Abstract][Full Text] [Related]
5. The IGF2 methylation score for adrenocortical cancer: an ENSAT validation study.
Creemers SG; Feelders RA; Valdes N; Ronchi CL; Volante M; van Hemel BM; Luconi M; Ettaieb MHT; Mannelli M; Chiara MD; Fassnacht M; Papotti M; Kerstens MN; Nesi G; Haak HR; van Kemenade FJ; Hofland LJ
Endocr Relat Cancer; 2020 Oct; 27(10):541-550. PubMed ID: 32668404
[TBL] [Abstract][Full Text] [Related]
6. Past, Present and Future of Epigenetics in Adrenocortical Carcinoma.
Ettaieb M; Kerkhofs T; van Engeland M; Haak H
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32414074
[TBL] [Abstract][Full Text] [Related]
7. TERT promoter hypermethylation is associated with poor prognosis in adrenocortical carcinoma.
Svahn F; Paulsson JO; Stenman A; Fotouhi O; Mu N; Murtha TD; Korah R; Carling T; Bäckdahl M; Wang N; Juhlin CC; Larsson C
Int J Mol Med; 2018 Sep; 42(3):1675-1683. PubMed ID: 29956721
[TBL] [Abstract][Full Text] [Related]
8. Future directions in the diagnosis and medical treatment of adrenocortical carcinoma.
Creemers SG; Hofland LJ; Korpershoek E; Franssen GJ; van Kemenade FJ; de Herder WW; Feelders RA
Endocr Relat Cancer; 2016 Jan; 23(1):R43-69. PubMed ID: 26475053
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic processes in sporadic parathyroid neoplasms.
Silva-Figueroa AM; Perrier ND
Mol Cell Endocrinol; 2018 Jul; 469():54-59. PubMed ID: 28400272
[TBL] [Abstract][Full Text] [Related]
10. Methylation of IGF2 regulatory regions to diagnose adrenocortical carcinomas.
Creemers SG; van Koetsveld PM; van Kemenade FJ; Papathomas TG; Franssen GJ; Dogan F; Eekhoff EM; van der Valk P; de Herder WW; Janssen JA; Feelders RA; Hofland LJ
Endocr Relat Cancer; 2016 Sep; 23(9):727-37. PubMed ID: 27535174
[TBL] [Abstract][Full Text] [Related]
11. Adrenocortical carcinoma: review of the pathologic features, production of adrenal steroids, and molecular pathogenesis.
Nakamura Y; Yamazaki Y; Felizola SJ; Ise K; Morimoto R; Satoh F; Arai Y; Sasano H
Endocrinol Metab Clin North Am; 2015 Jun; 44(2):399-410. PubMed ID: 26038208
[TBL] [Abstract][Full Text] [Related]
12. Current and emerging therapies for adrenocortical carcinoma--review.
Przytulska J; Rogala N; Bednarek-Tupikowska G
Adv Clin Exp Med; 2015; 24(2):185-93. PubMed ID: 25931348
[TBL] [Abstract][Full Text] [Related]
13. Dosage-dependent regulation of
Ruggiero C; Doghman-Bouguerra M; Sbiera S; Sbiera I; Parsons M; Ragazzon B; Morin A; Robidel E; Favier J; Bertherat J; Fassnacht M; Lalli E
Sci Signal; 2017 Mar; 10(469):. PubMed ID: 28270555
[TBL] [Abstract][Full Text] [Related]
14. Adrenocortical carcinoma: review and update.
Erickson LA; Rivera M; Zhang J
Adv Anat Pathol; 2014 May; 21(3):151-9. PubMed ID: 24713984
[TBL] [Abstract][Full Text] [Related]
15. DNA methylation and histone modifications in patients with cancer: potential prognostic and therapeutic targets.
Herranz M; Esteller M
Methods Mol Biol; 2007; 361():25-62. PubMed ID: 17172706
[TBL] [Abstract][Full Text] [Related]
16. Epigenetically maintained SW13+ and SW13- subtypes have different oncogenic potential and convert with HDAC1 inhibition.
Davis MR; Daggett JJ; Pascual AS; Lam JM; Leyva KJ; Cooper KE; Hull EE
BMC Cancer; 2016 May; 16():316. PubMed ID: 27188282
[TBL] [Abstract][Full Text] [Related]
17. MANAGEMENT OF ENDOCRINE DISEASE: Adrenocortical carcinoma: differentiating the good from the poor prognosis tumors.
Jouinot A; Bertherat J
Eur J Endocrinol; 2018 May; 178(5):R215-R230. PubMed ID: 29475877
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic Modifications and Head and Neck Cancer: Implications for Tumor Progression and Resistance to Therapy.
Castilho RM; Squarize CH; Almeida LO
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28704968
[TBL] [Abstract][Full Text] [Related]
19. Identification of a CpG island methylator phenotype in adrenocortical carcinomas.
Barreau O; Assié G; Wilmot-Roussel H; Ragazzon B; Baudry C; Perlemoine K; René-Corail F; Bertagna X; Dousset B; Hamzaoui N; Tissier F; de Reynies A; Bertherat J
J Clin Endocrinol Metab; 2013 Jan; 98(1):E174-84. PubMed ID: 23093492
[TBL] [Abstract][Full Text] [Related]
20. Epigenetics of pituitary tumors: Pathogenetic and therapeutic implications.
Ezzat S; Cheng S; Asa SL
Mol Cell Endocrinol; 2018 Jul; 469():70-76. PubMed ID: 28711607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
